Embecta Corp.
$3.44 +$0.15 (+4.41%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 27
Chatter ran way louder than usual.
2 mentions across the stream that day (+3.8σ vs its own baseline) — attention, not direction. Loud days mark where the crowd was looking.
RECEIPT: NARRATIVE VELOCITY, 30-DAY BASELINE -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jun 26
The stock moved +12.2% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jun 26 -
May 19
From its Feb 4 high, the share price fell 74%.
Peak close $11.35 on Feb 4; trough close $2.90 on May 19. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -74% -
May 5
The stock moved -57.8% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 5
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.